Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KYMR | 48.02% | $2.47B | +35.74% | 0.00% |
DLX | 46.81% | $939.01M | +5.79% | 5.70% |
SCSC | 46.51% | $1.13B | +23.76% | 0.00% |
DNLI | 46.45% | $2.75B | +3.02% | 0.00% |
RCKT | 46.15% | $1.18B | -61.06% | 0.00% |
RCUS | 46.14% | $1.30B | -18.90% | 0.00% |
MOG.A | 45.57% | $6.75B | +40.44% | 0.57% |
ITT | 45.15% | $11.33B | +18.33% | 0.92% |
ALLO | 44.95% | $430.88M | -36.18% | 0.00% |
BEAM | 44.72% | $2.19B | +3.09% | 0.00% |
MGTX | 44.71% | $484.55M | -2.52% | 0.00% |
VCTR | 44.38% | $3.99B | +80.84% | 2.55% |
EVR | 44.33% | $10.01B | +56.56% | 1.22% |
CRSP | 43.84% | $3.39B | -38.23% | 0.00% |
MHO | 43.70% | $3.38B | -4.46% | 0.00% |
APAM | 43.68% | $2.85B | -2.91% | 7.03% |
AEIS | 43.66% | $4.46B | +15.79% | 0.35% |
JHG | 43.46% | $6.47B | +39.61% | 3.87% |
TPG | 43.38% | $6.08B | +57.89% | 2.68% |
BN | 43.24% | $82.83B | +40.15% | 0.59% |
Yahoo
Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Yahoo
Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
Yahoo
There are two cell therapies approved in this patient setting, Johnson & Johnson’s Carvykti and Bristol Myers Squibb's Abecma.
Yahoo
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.
Yahoo
On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The data will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. Anito-cel is partnered with Kite, a Gilead Science Inc’s (NASDAQ:GILD) company. Also Read: Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Mye
Finnhub
Arcellx Announces New Positive Data for its iMMagine-1 Study in Patients with Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -19.60% | $19.99B | +5.68% | 1.23% |
HUSA | -18.04% | $21.99M | -1.18% | 0.00% |
K | -14.24% | $28.10B | +47.08% | 2.77% |
PSQH | -10.32% | $167.01M | -23.48% | 0.00% |
CYCN | -9.86% | $8.92M | -9.86% | 0.00% |
TCTM | -9.10% | $6.23M | -37.75% | 0.00% |
BTCT | -8.64% | $20.70M | -28.47% | 0.00% |
SYPR | -6.08% | $49.73M | +2.37% | 0.00% |
TRVG | -5.85% | $51.84M | -3.35% | 0.00% |
STG | -5.09% | $28.83M | -36.52% | 0.00% |
DAO | -4.95% | $204.25M | +74.40% | 0.00% |
PRPH | -4.51% | $15.49M | -86.76% | 0.00% |
HSY | -4.23% | $32.01B | -17.02% | 3.45% |
PEP | -4.06% | $195.70B | -14.72% | 3.72% |
DOGZ | -3.98% | $528.07M | +887.62% | 0.00% |
PULM | -3.87% | $21.95M | +206.95% | 0.00% |
FUBO | -3.82% | $1.71B | +87.18% | 0.00% |
UUU | -3.75% | $5.37M | +44.10% | 0.00% |
PCRX | -3.56% | $953.01M | -35.95% | 0.00% |
LU | -3.52% | $1.99B | -6.69% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMRN | -0.09% | $11.17M | -0.51% | 0.00% |
APT | 0.19% | $63.46M | +9.90% | 0.00% |
UNH | -0.21% | $479.18B | -0.16% | 1.53% |
PRPO | -0.22% | $9.09M | +14.66% | 0.00% |
FINV | -0.29% | $984.07M | +40.42% | 3.59% |
CCEC | 0.45% | $1.01B | +7.48% | 3.29% |
XBIO | 0.45% | $5.95M | +0.52% | 0.00% |
GIS | 0.60% | $32.25B | -7.71% | 4.05% |
LITB | -0.63% | $25.37M | -77.88% | 0.00% |
COR | -0.69% | $45.65B | +7.64% | 0.88% |
ACCD | 0.77% | $550.07M | -50.97% | 0.00% |
PHG | 0.78% | $24.12B | +11.63% | 0.00% |
MCK | -0.94% | $73.85B | +19.87% | 0.46% |
ZCMD | -0.95% | $45.13M | -44.92% | 0.00% |
TTE | -0.98% | $129.26B | -14.55% | 5.90% |
CME | 1.00% | $82.59B | +16.03% | 4.54% |
NOAH | -1.03% | $672.35M | -8.06% | 10.39% |
SRRK | -1.10% | $3.79B | +147.95% | 0.00% |
CMBT | 1.19% | $2.15B | -36.76% | 9.80% |
CATO | 1.21% | $71.68M | -50.28% | 14.87% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 60.35% | $122.11M | 0.6% |
XBI | 59.74% | $6.43B | 0.35% |
RSPA | 59.06% | $270.45M | 0% |
IWC | 56.84% | $960.03M | 0.6% |
IWO | 55.96% | $12.80B | 0.24% |
VTWO | 55.94% | $12.36B | 0.1% |
IWM | 55.75% | $71.90B | 0.19% |
IBB | 55.22% | $6.45B | 0.45% |
SMMD | 54.97% | $1.37B | 0.15% |
VXF | 54.81% | $21.54B | 0.06% |
NUSC | 54.68% | $1.23B | 0.31% |
ISCG | 54.51% | $642.78M | 0.06% |
FSMD | 54.43% | $669.24M | 0.16% |
ESML | 54.42% | $1.89B | 0.17% |
GSSC | 54.42% | $529.07M | 0.2% |
PSC | 53.97% | $734.03M | 0.38% |
PRFZ | 53.82% | $2.55B | 0.39% |
VB | 53.72% | $63.74B | 0.05% |
IWN | 53.33% | $12.17B | 0.24% |
SMLF | 53.26% | $1.51B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BCD | 0.08% | $233.64M | 0.3% |
BCI | 0.09% | $1.31B | 0.26% |
SGOV | 0.12% | $30.83B | 0.09% |
CCOR | -0.21% | $83.85M | 1.18% |
GXC | 0.30% | $386.96M | 0.59% |
DBC | -0.31% | $1.30B | 0.87% |
XONE | 0.69% | $540.66M | 0.03% |
CMDY | -0.77% | $287.70M | 0.28% |
IBTF | 1.34% | $2.23B | 0.07% |
FTGC | -1.41% | $2.25B | 1.02% |
FLCH | 1.50% | $141.60M | 0.19% |
BILZ | 1.50% | $614.54M | 0.14% |
PDBC | -1.51% | $4.15B | 0.59% |
MINT | -1.62% | $12.00B | 0.35% |
IVOL | -1.65% | $455.77M | 1.02% |
DBO | -1.74% | $214.31M | 0.77% |
MCHI | 2.37% | $5.20B | 0.6% |
CXSE | 2.40% | $366.89M | 0.32% |
UNG | -2.44% | $790.37M | 1.06% |
GBIL | 2.70% | $5.82B | 0.12% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -42.42% | $195.31M | 0.85% |
TAIL | -26.52% | $65.56M | 0.59% |
WEAT | -15.68% | $119.67M | 0.28% |
USDU | -13.67% | $381.18M | 0.5% |
CTA | -13.41% | $497.20M | 0.76% |
CORN | -12.39% | $63.58M | 0.2% |
TPMN | -11.46% | $41.63M | 0.65% |
UUP | -9.06% | $607.07M | 0.77% |
SOYB | -8.01% | $24.83M | 0.22% |
USCI | -6.82% | $193.45M | 1.07% |
XHLF | -5.51% | $939.87M | 0.03% |
DBA | -5.06% | $790.77M | 0.93% |
CLOI | -4.80% | $792.86M | 0.4% |
DBE | -3.85% | $48.12M | 0.77% |
XBIL | -3.63% | $641.82M | 0.15% |
AGZD | -3.27% | $142.77M | 0.23% |
GSG | -2.89% | $1.02B | 0.75% |
COMT | -2.79% | $688.84M | 0.48% |
UNG | -2.44% | $790.37M | 1.06% |
DBO | -1.74% | $214.31M | 0.77% |
Current Value
$68.511 Year Return
Current Value
$68.511 Year Return